Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: Simulations reveal complexities of modulation

Phosphorylation of S17 in the N-terminal "lid" of MDM2 (residues 1-24) is proposed to regulate the binding of p53. The lid is composed of an intrinsically disordered peptide motif that is not resolved in the crystal structure of the MDM2 N-terminal domain. Molecular dynamics simulations of MDM2 provide novel insight into how the lid undergoes complex dynamics depending on its phosphorylation state that have not been revealed by NMR analyses. The difference in charges between the phosphate and the phosphomimetic 'Asp' and the change in shape from tetrahedral to planar are manifested in differences in strengths and durations of interactions that appear to modulate access of the binding site to ligands and peptides differentially. These findings unveil the complexities that underlie protein-protein interactions and reconcile some differences between the biochemical and NMR data suggesting that lid mutation or deletion can change the specific activity of MDM2 and provide concepts for future approaches to evaluate the effects of S17 modification on p53 binding.

[1]  Matthew P. Jacobson,et al.  Conformational Changes in Protein Loops and Helices Induced by Post-Translational Phosphorylation , 2006, PLoS Comput. Biol..

[2]  Paul N Barlow,et al.  Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. , 2005, Journal of molecular biology.

[3]  J. Turchi,et al.  Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. , 1997, Cancer research.

[4]  D. Lane,et al.  Design of a novel MDM2 binding peptide based on the p53 family , 2009, Cell cycle.

[5]  David P. Lane,et al.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.

[6]  M. Walkinshaw,et al.  The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. , 2010, Journal of molecular biology.

[7]  Deepak Srinivasan,et al.  Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study , 2007, Cell cycle.

[8]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[9]  Rafael Brüschweiler,et al.  Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. , 2008, Journal of the American Chemical Society.

[10]  T. Shinohara,et al.  [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[11]  Chandra S. Verma,et al.  Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100 , 2009, BMC Bioinformatics.

[12]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[13]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[14]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[15]  M. Walkinshaw,et al.  Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif , 2009, Journal of chemical biology.

[16]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[17]  Shubhra Ghosh Dastidar,et al.  Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2 , 2010 .

[18]  C. Klein,et al.  p53--a natural cancer killer: structural insights and therapeutic concepts. , 2006, Angewandte Chemie.

[19]  A. Fersht,et al.  Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. , 2004, Journal of molecular biology.

[20]  Shubhra Ghosh Dastidar,et al.  Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. , 2008, Journal of the American Chemical Society.

[21]  Deepak Srinivasan,et al.  The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides , 2008, Cell cycle.

[22]  M. McCoy,et al.  Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Verma,et al.  Why an A-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations. , 2010, Structure.

[24]  H. Carlson,et al.  Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.